ARPO — Aerpio Pharmaceuticals Share Price
Last Trade - 00:00- $109.20m
- $70.19m
- $15.00m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 20.16 | n/a | 15 | n/a | 2.88 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The Company is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The Company's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.
Directors
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- November 16th, 2007
- Public Since
- June 26th, 2018
- No. of Shareholders
- 113
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 47,477,084
- Address
- 9987 Carver Rd, BLUE ASH, 45242-5550
- Web
- https://aerpio.com/
- Phone
- +1 5139851920
- Auditors
- Ernst & Young LLP
Latest News for ARPO
Upcoming events for ARPO
Q3 2021 Aerpio Pharmaceuticals Inc Earnings Release
Similar to ARPO
180 LIFE SCIENCES ORD
NASDAQ Capital Market
9 METERS BIOPHARMA ORD
NASDAQ Capital Market
ABVC BIOPHARMA ORD
NASDAQ Capital Market
ACER THERAPEUTICS ORD
NASDAQ Capital Market
ADIAL PHARMACEUTICALS ORD
NASDAQ Capital Market
FAQ
As of Today at 19:56 UTC, shares in Aerpio Pharmaceuticals are trading at $2.30. This share price information is delayed by 15 minutes.
Shares in Aerpio Pharmaceuticals last closed at $2.30 and the price had moved by +38.55% over the past 365 days. In terms of relative price strength the Aerpio Pharmaceuticals share price has outperformed the S&P500 Index by +5.12% over the past year.
The overall consensus recommendation for Aerpio Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aerpio Pharmaceuticals does not currently pay a dividend.
Aerpio Pharmaceuticals does not currently pay a dividend.
Aerpio Pharmaceuticals does not currently pay a dividend.
To buy shares in Aerpio Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.30, shares in Aerpio Pharmaceuticals had a market capitalisation of $109.20m.
Here are the trading details for Aerpio Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ARPO
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Aerpio Pharmaceuticals does not currently have a style classification.
The analyst consensus target price for shares in Aerpio Pharmaceuticals is $22.00. That is 856.52% above the last closing price of $2.30.
Analysts covering Aerpio Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.39 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aerpio Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +3.66%.
As of the last closing price of $2.30, shares in Aerpio Pharmaceuticals were trading +43.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aerpio Pharmaceuticals.
We do not have data on Aerpio Pharmaceuticals' directors
We do not have data on Aerpio Pharmaceuticals' shareholders